Prognostic value of seminal vesicle involvement due to prostate cancer in radical prostatectomy specimens

被引:5
作者
Algarra, R. [1 ]
Barba, J. [1 ]
Merino, I. [1 ]
Tienza, A. [1 ]
Tolosa, E. [1 ]
Robles, J. E. [1 ]
Zudaire, J. [1 ]
机构
[1] Univ Navarra Clin, Dept Urol, Pamplona, Spain
来源
ACTAS UROLOGICAS ESPANOLAS | 2015年 / 39卷 / 03期
关键词
Prostate cancer; Biochemical progression; Prostate specific antigen; Gleason; Rescue therapy; ANDROGEN ABLATION THERAPY; HORMONAL-THERAPY; ANTIGEN; PROGRESSION; CARCINOMA; RADIATION; SURVIVAL; RISK; ADENOCARCINOMA; INVASION;
D O I
10.1016/j.acuro.2014.05.009
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To study the influence, in terms of prognosis, of the finding of seminal vesicle involvement in patients with prostate adenocarcinoma treated with radical prostatectomy. Material and method: We reviewed a series of patients with seminal vesicle involvement with clinically localized prostate adenocarcinoma who underwent radical prostatectomy between 1989 and 2009, focusing on their clinical-pathological characteristics, biochemical progression-free survival (BPFS) and specific survival (SS). We assessed the variables that influenced BPFS and designed a risk model. Results: A total of 127 out of 1,132 patients who underwent surgery (11%) presented seminal vesicle invasion (i.e., pT3b). In the multivariate study of the entire series (Cox model), pT3b affects the BPFS (HR: 2; 95% CI: 1.4-3.3; P=.001). Other influential factors were the affected borders, initial prostate-specific antigen levels, pathological Gleason score and the presence of palpated tumor. The pT3b tumors have poorer clinical-pathological variables when compared with pT2 and pT3a tumors. Sixty-five percent of the patients evidenced biochemical progression. The BPFS was significantly poorer for pT3b (40 +/- 4% and 28 4% at 5 and 10 years, respectively) than for pT2 and pT3a (P<.0001). The SS was also poorer in patients with pT3b tumors (91 +/- 2% and 76 +/- 4% at 5 and 10 years, respectively) (P<.0001). The predictors within the pT3b patient group were: PSA levels >10 ng/mL (HR: 1.9; 95% CI: 1.04-3.6; P=.04) and pathological Gleason score 8-10 (HR: 2.1; 95% CI: 1.2-3.5; P=.03). We designed a risk model that accounts for the variables involved, which entails 2 groups with different BPFS (P=.004): Group 1 (0-1 variable), with a BPFS of 46 +/- 7% and 27 +/- 8% at 5 and 10 years, respectively; and Group 2 (2 variables), with a BPFS of 14 +/- 7% and 5 +/- 5% at 5 and 10 years, respectively. Conclusion: Seminal vesicle involvement severely and negatively affects the BPFS and SS. We designed a risk model with the independent influential variables in BPFS (pathological Gleason score 8-10 and PSA levels >10 ng/mL). This model confirms that pT3b tumors are a heterogeneous group, which includes an important group with better prognosis when surgical treatment is performed. (C) 2014 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:144 / 153
页数:10
相关论文
共 44 条
[11]   Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE) [J].
Cooperberg, MR ;
Lubeck, DP ;
Mehta, SS ;
Carroll, PR .
JOURNAL OF UROLOGY, 2003, 170 (06) :S21-S25
[12]  
Cox JD, 1999, J CLIN ONCOL, V17, P1155
[13]   The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Fondurulia, J ;
Chen, MH ;
Tomaszewski, JE ;
Wein, A .
JOURNAL OF UROLOGY, 1998, 160 (06) :2096-2101
[14]   Prognostic significance of seminal vesicle invasion on the radical prostatectomy specimen - Rationale for seminal vesicle biopsies [J].
Debras, B ;
Guillonneau, B ;
Bougaran, J ;
Chambon, E ;
Vallancien, G .
EUROPEAN UROLOGY, 1998, 33 (03) :271-277
[15]   Adenocarcinoma of the prostate invading the seminal vesicle: Prognostic stratification based on pathologic parameters [J].
Epstein, JI ;
Partin, AW ;
Potter, SR ;
Walsh, PC .
UROLOGY, 2000, 56 (02) :283-288
[16]   THE ROGERS,WILL PHENOMENON - STAGE MIGRATION AND NEW DIAGNOSTIC-TECHNIQUES AS A SOURCE OF MISLEADING STATISTICS FOR SURVIVAL IN CANCER [J].
FEINSTEIN, AR ;
SOSIN, DM ;
WELLS, CK .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (25) :1604-1608
[17]  
Forman JD, 1998, ONCOLOGY-NY, V12, P33
[18]   Adjuvant therapy in high risk prostate cancer: The argument PRO [J].
Hammerer, P .
EUROPEAN UROLOGY SUPPLEMENTS, 2004, 3 (03) :39-42
[19]   RELATIONSHIP BETWEEN TUMOR SIZE AND THE CURABILITY OF METASTATIC PROSTATIC-CANCER BY SURGERY ALONE OR IN COMBINATION WITH ADJUVANT CHEMOTHERAPY [J].
HENRY, JM ;
ISAACS, JT .
JOURNAL OF UROLOGY, 1988, 139 (05) :1119-1123
[20]   THE TIMING OF ANDROGEN ABLATION THERAPY AND OR CHEMOTHERAPY IN THE TREATMENT OF PROSTATIC-CANCER [J].
ISAACS, JT .
PROSTATE, 1984, 5 (01) :1-17